Clozapine, an atypical antipsychotic used primarily to treat schizophrenia, was developed in the 1960s and introduced into clinical use in several European countries in the 1970s. Its history is notable for its strong effectiveness in treatment-resistant schizophrenia, but also for the discovery of a potentially life-threatening side effect agranulocytosis (a severe drop in white blood cells) which led to its temporary withdrawal or restricted use in multiple markets. Clozapine was later reintroduced with strict blood monitoring requirements.

BRAND NAMES

  • Clozaril

  • Leponex

  • FazaClo

  • Versacloz

MECHANISM OF ACTION

Clozapine works primarily by blocking multiple neurotransmitter receptors in the brain, especially serotonin (5-HT2A) and dopamine receptors (with relatively higher affinity for D4 than D2). This balanced dopamine-serotonin antagonism helps reduce psychotic symptoms while causing fewer movement-related side effects than typical antipsychotics. It also affects histamine, muscarinic, and alpha-adrenergic receptors, which contributes to side effects like sedation, weight gain, and orthostatic hypotension.

PHARMACOKINETICS

Absorption

Clozapine is well absorbed after oral administration, with an approximate bioavailability of about 50–60% due to significant first-pass metabolism in the liver. Peak plasma concentrations are usually reached within 1.5 to 4 hours after dosing, though food may slightly delay absorption without greatly affecting overall exposure. Its absorption is not significantly affected by antacids, but smoking can reduce plasma levels by inducing hepatic enzymes that increase drug metabolism.

Distribution

Clozapine has a large volume of distribution, approximately 1.6–7 L/kg, indicating extensive distribution into tissues. It is highly lipophilic and about 95% bound to plasma proteins, mainly albumin and alpha-1 acid glycoprotein. Because of this extensive tissue binding, clozapine readily crosses the blood–brain barrier, contributing to its central nervous system effects.

Metabolism

Clozapine is extensively metabolized in the liver, mainly by the cytochrome P450 enzyme system, especially CYP1A2(primary pathway), with contributions from CYP3A4 and CYP2D6. It undergoes N-demethylation and oxidation to form active and inactive metabolites, the most important active metabolite being norclozapine (desmethylclozapine).

Elimination

Clozapine is mainly eliminated after hepatic metabolism, with most of the drug excreted as metabolites in urine (about 50–60%) and feces (about 30–40%). It has an elimination half-life of roughly 12 hours, which can vary based on liver enzyme activity, smoking, and drug interactions.

PHARMACODYNAMICS

Clozapine shows complex pharmacodynamics due to its action on multiple neurotransmitter systems. It primarily acts as an antagonist at serotonin (5-HT2A) and dopamine (D4 > D2) receptors, which helps reduce both positive and negative symptoms of schizophrenia while producing fewer extrapyramidal side effects. It also blocks muscarinic (M1)histamine (H1), and alpha-1 adrenergic receptors, contributing to effects such as sedation, anticholinergic symptoms, weight gain, and orthostatic hypotension

ADMINISTRATION

Clozapine is given orally as tablets, orally disintegrating tablets, or liquid suspension. Treatment starts with a very low dose that is slowly increased over time to reduce side effects like hypotension and sedation. Once a stable effective dose is reached, it is taken once or twice daily as maintenance therapy. Regular blood monitoring is required throughout treatment to ensure safety.

DOSAGE AND STRENGTH

Clozapine is available in multiple strengths to allow careful titration. Common tablet strengths include 25 mg, 50 mg, 100 mg, and 200 mg. In clinical use, the starting dose is usually 12.5 mg once or twice daily, with gradual increases based on tolerance. The usual maintenance dose ranges from 300–450 mg per day, divided into 1–2 doses, while the maximum recommended dose is about 900 mg per day in selected cases under strict monitoring.

DRUG INTERACTIONS

Clozapine has several clinically important drug interactions, mainly due to CYP450 metabolism (especially CYP1A2).

1. CYP1A2 inhibitors (increase clozapine levels → toxicity risk)

  • Fluvoxamine, ciprofloxacin, erythromycin, ciprofloxacin (strong effect)

  • Can lead to sedation, seizures, hypotension, or toxicity

2. CYP1A2 inducers (decrease clozapine levels → reduced efficacy)

  • Smoking (tobacco), carbamazepine, phenytoin, rifampicin

  • May require dose increase in smokers or during induction

3. CNS depressants (additive sedation)

  • Alcohol, benzodiazepines, opioids

  • Increased risk of respiratory depression, sedation, and hypotension

FOOD INTERACTIONS

Clozapine has minimal direct food interactions. However, caffeine intake can affect its levels because both are metabolized by CYP1A2, so sudden increases or decreases in caffeine may alter drug concentration and side effects. High-fat meals may slightly delay absorption but do not significantly change overall effectiveness.

CONTRAINDICATIONS

Clozapine is contraindicated in patients with a history of severe neutropenia or agranulocytosis, known hypersensitivity to the drug, uncontrolled epilepsy, or severe CNS depression. It should also not be used in patients who cannot comply with mandatory regular blood monitoring due to the risk of life-threatening blood dyscrasias.

SIDE EFFECTS

  • Sedation 

  • Weight gain 

  • Hypersalivation 

  • Constipation 

  • Dizziness 

  • Tachycardia 

OVER DOSE

  • Severe CNS depression (drowsiness, coma) 

  • Respiratory depression 

  • Seizures 

  • Severe hypotension 

  • Tachycardia and arrhythmias 

  • Delirium or confusion 

  • Hypersalivation 

  • Aspiration risk 

TOXICITY

Clozapine toxicity happens when drug levels become too high, leading to severe drowsiness, confusion, seizures, low blood pressure, and fast heart rate.Treatment is supportive and emergency-based, as there is no specific antidote.

Image
Slide_1
CAS Number
Clozapine STD -5786-21-0 ; IMP-A-50892-62-1;IMP-B- 263366-81-0 ;IMP-C-6104-71-8 ;IMP-D-65514-71-8 ;
CAS Number
109-01-3
Alternate CAS Number
34352-59-5(DiHCl Salt)